# FIGHT-202 (NCT02924376)

> Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

No report yet. It can be ordered.

- Drugs tested: pemigatinib
- Indication: previously treated advanced or metastatic cholangiocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02924376
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: Cholangiocarcinoma
- Interventions: Pemigatinib
- Enrollment: 147
- Primary outcome: Objective Response Rate (ORR) in Participants With FGFR2 Rearrangements or Fusions

## Indexed commentary on FIGHT-202 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 31
- Podcasts: 8
- YouTube: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=fight-202-nct02924376

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02924376", "email": "<work email>"}; the inbox owner confirms by the emailed link.